급성 신손상(AKI) 질환 치료 시장 : 예측(2025-2030년)

The acute kidney injury (AKI) disease treatment market is predicted to grow at a CAGR of 7.50% from US$2.004 billion in 2025 to US$2.875 billion by 2030.

The global market for acute renal injury treatment is significantly influenced by the rising incidence of acute kidney damage. The National Kidney Foundation estimates that kidney illnesses impact about 37 million people in the US. Kidney injury risk has increased as a result of an aging population, poor diet, and heavy alcohol use. Acetaminophen and other drug overdoses, hepatitis, autoimmune disorders, and metabolic diseases are other causes contributing to the market's explosive expansion. Additionally, it is projected that rising healthcare costs and government measures to improve the healthcare system will boost market revenue. However, the market expansion is being hampered by the high cost of dialysis services and the low compliance from patients for long-term treatment plans.

Acute kidney injury disease treatment market drivers:

• Increase in lifestyle-related diseases and technological advancements.

Acute kidney injury results in sudden and temporary loss of the function of the kidney. This could occur due to several underlying diseases like diabetes and high blood pressure. A slew of diseases is cropping up due to the changing lifestyles of people. Some of the prominent examples are diabetes, obesity, hypertension, and other liver or kidney-related diseases. The World Health Organisation estimates that 60% of the variables affecting a person's health and quality of life are related to their way of living. People's health is being impacted by processed and junk food as well as poor eating habits. Additionally, a lack of exercise and movement increases the risk of dyspepsia and subsequent acute renal damage.

People are developing addictions to drugs, alcohol, and smoking, all of which have detrimental effects on their health. Lack of physical movement and exercise is also increasing the likelihood of indigestion, and consequent acute kidney injuries. People are getting addicted to alcohol, smoking, and drugs which also have adverse implications for their health. For instance, the International Society of Nephrology estimates that there are over 13.3 million cases of acute renal damage each year throughout the world. Globally, acute renal damage also results in 1.7 million deaths each year. AKI is present in about 1% of hospitalized patients in the United States.

Moreover, AKI occurs in more than 50% of patients in intensive care units (ICU) and occurs within 30 days of surgery in about 1% of general surgical cases. Additionally, according to the 2023 report of the National Institute of Diabetes and Digestive and Kidney Diseases, 2 in 1000 Americans have end-stage kidney illness, with 71% relying on dialysis and 29% receiving a kidney transplant. The need for precise and effective treatment is growing along with the prevalence of renal disorders.

Acute kidney injury (AKI) disease treatment market geographical outlook:

• The acute kidney injury disease treatment market is segmented into five regions worldwide

The North American AKI disease treatment market has been segmented into the United States, Canada, and Mexico and is estimated to grow at a significant CAGR during the forecast period. The high prevalence of diabetes in the U.S. is increasing the number of people with acute kidney injury. According to the Centers for Disease Control and Prevention (CDC), AKI is a significant public health problem in the United States, affecting over 500,000 people each year and resulting in more than 100,000 deaths. AKI is also associated with increased healthcare costs, with hospitalizations for AKI costing an estimated $10 billion annually in the US. Moreover, there is increasing adoption of innovative treatment options, such as renal replacement therapies (RRTs), which include hemodialysis and peritoneal dialysis. These treatments are becoming more widely available and affordable, allowing more patients to access the care they need.

Furthermore, the prevalence of the various causes of AKI can guide future research and development in the AKI treatment market. For instance, given that urinary tract obstruction is a significant cause of AKI, there may be an opportunity for drug developers to focus on developing therapies that address this condition, especially in older men with benign prostatic hypertrophy.

Reasons for buying this report:-

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data & forecasts from 2022 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The Acute kidney injury disease treatment market is segmented and analyzed as follows:

By Component

• Treatment
• Drug Type
• Isotonic Solution
• Antibiotic
• Others
• Dialysis
• Diagnosis
• Urine Test
• Blood Test
• Glomerular Filtration Rate (GFR)
• Imaging Test
• Biopsy

By Type of RRT

• Continuous
• Intermittent

By Geography

• North America

By Component

By Type of RRT

By Country

• USA
• Canada
• Mexico
• South America

By Component

By Type of RRT

By Country

• Brazil
• Argentina
• Others
• Europe

By Component

By Type of RRT

By Country

• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa

By Component

By Type of RRT

By Country

• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific

By Component

By Type of RRT

By Country

• China
• Japan
• South Korea
• India
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base and Forecast Years Timeline
• 1.8. Key Benefits for the Stakeholders

2. RESEARCH METHODOLOGY

• 2.1. Research Design
• 2.2. Research Process

3. EXECUTIVE SUMMARY

• 3.1. Key Findings
• 3.2. Analyst View

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Supplier
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. ACUTE KIDNEY INJURY DISEASE TREATMENT MARKET BY COMPONENT

• 5.1. Introduction
• 5.2. Treatment
  • 5.2.1. Drug Type
    • 5.2.1.1. Isotonic Solution
    • 5.2.1.2. Antibiotic
    • 5.2.1.3. Others
  • 5.2.2. Dialysis
• 5.3. Diagnosis
  • 5.3.1. Urine Test
  • 5.3.2. Blood Test
  • 5.3.3. Glomerular Filtration Rate (GFR)
  • 5.3.4. Imaging Test
  • 5.3.5. Biopsy

6. ACUTE KIDNEY INJURY DISEASE TREATMENT MARKET BY TYPE OF RRT

• 6.1. Introduction
• 6.2. Continuous
• 6.3. Intermittent

7. ACUTE KIDNEY INJURY DISEASE TREATMENT MARKET BY GEOGRAPHY

• 7.1. Introduction
• 7.2. North America
  • 7.2.1. By Component
  • 7.2.2. By Type of RRT
  • 7.2.3. By Country
    • 7.2.3.1. USA
    • 7.2.3.2. Canada
    • 7.2.3.3. Mexico
• 7.3. South America
  • 7.3.1. By Component
  • 7.3.2. By Type of RRT
  • 7.3.3. By Country
    • 7.3.3.1. Brazil
    • 7.3.3.2. Argentina
    • 7.3.3.3. Others
• 7.4. Europe
  • 7.4.1. By Component
  • 7.4.2. By Type of RRT
  • 7.4.3. By Country
    • 7.4.3.1. Germany
    • 7.4.3.2. France
    • 7.4.3.3. United Kingdom
    • 7.4.3.4. Spain
    • 7.4.3.5. Others
• 7.5. Middle East and Africa
  • 7.5.1. By Component
  • 7.5.2. By Type of RRT
  • 7.5.3. By Country
    • 7.5.3.1. Saudi Arabia
    • 7.5.3.2. UAE
    • 7.5.3.3. Israel
    • 7.5.3.4. Others
• 7.6. Asia Pacific
  • 7.6.1. By Component
  • 7.6.2. By Type of RRT
  • 7.6.3. By Country
    • 7.6.3.1. China
    • 7.6.3.2. Japan
    • 7.6.3.3. South Korea
    • 7.6.3.4. India
    • 7.6.3.5. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 8.1. Major Players and Strategy Analysis
• 8.2. Market Share Analysis
• 8.3. Mergers, Acquisitions, Agreements, and Collaborations
• 8.4. Competitive Dashboard

9. COMPANY PROFILES

• 9.1. Exponential Biotherapies, Inc.
• 9.2. Nikkiso America, Inc.
• 9.3. Am-Pharma
• 9.4. Renalguard Solutions, Inc.
• 9.5. Angion Biomedica Corp.
• 9.6. Thrasos Therapeutics Inc.
• 9.7. Atoxbio
• 9.8. Sentien Biotechnologies, Inc